Host-pathogen Interactions, Immune Response, and Clinical Prognosis at COVID-19 - the CoVUm Trial
Study Details
Study Description
Brief Summary
The project aims to clarify how immunity to SARS-CoV2 develops in humans and to investigate the possibility of finding patients with a particularly effective, neutralizing antibody response for future treatment. The project also aims to detail the virus's damage mechanisms in tissue.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
N/A |
Detailed Description
There is currently no specific treatment for COVID-19 caused by SARS-CoV2. By gaining more knowledge about the mechanisms in the development of viral pneumonia and the influence of other organ systems at SARS-CoV2, we believe that in the future it is better to be able to identify precisely those persons who are at risk of serious illness. To this we will gain knowledge of how humans develops immunity to the virus and also how human epigenetic (acquired) ability to activate inflammatory genetic systems can limit the harmful effects of the virus. Thus, patients who have had mild or no symptoms are just as interesting from a study point of view as those who have had severe symptoms. Hopefully, such understanding can also contribute to other opportunities for targeted treatment (by identifying patients who can mount effective inborn and adaptive host defenses) in order to prevent severe disease and death in pandemic corona infection.
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: Experimental The difference from the standard of care is extended sample collection and study related procedures during the study. |
Procedure: Extended sampling and procedures
The study patients will give additional blood samples and also urine and faeces samples. Spirometry and additional biometric controls will be performed regularly. Necrobiopsies of various organs from deceased patients will be secured and stored for immunohistological and virological analysis.
|
Outcome Measures
Primary Outcome Measures
- Mortality [Five years after study start]
Deceased or alive at five year follow-up
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Patients between 15-100 years with SARS-CoV2
-
Patients admitted for COVID-19-caused pneumonia / pneumonitis at the Department of Infectious Diseases or ICU, Umeå University Hospital.
-
Patients with COVID-19 who are treated in outpatient care at the infectious Diseases Clinic, Umeå University Hospital.
-
Patients who give written informed consent to participate in the study for the entire follow- up period of 5 years.
Exclusion Criteria:
- Age less than 15 years
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Incectious Diseases Clinic | Umeå | Västerbotten | Sweden | 90189 |
Sponsors and Collaborators
- Johan Normark
- Umeå University
- Region Västerbotten
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- CoVUm